Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Published online before print May 23, 2007, doi:10.1212/01.wnl.0000265517.66976.28)
This Article
Right arrow Full Text (Rapid PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
01.wnl.0000265517.66976.28v1
69/1/91    most recent
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Halperin, J. J.
Right arrow Articles by Bever, C. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Halperin, J. J.
Right arrow Articles by Bever, C. T., Jr.
Received December 26, 2006
Accepted March 7, 2007

Practice Parameter: Treatment of nervous system Lyme disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

J. J. Halperin MD, E. D. Shapiro MD, E. Logigian MD, A. L. Belman MD, L. Dotevall MD, G. P. Wormser MD, L. Krupp MD, G. Gronseth MD, and C. T. Bever Jr. MD

From the Department of Neurosciences (J.J.H.), Overlook Hospital, NYU School of Medicine, Summit, NJ; Departments of Pediatrics and Epidemiology and Public Health (E.D.S.), Yale University School of Medicine, New Haven, CT; Department of Neurology (E.L.), University of Rochester School of Medicine and Dentistry, NY; Department of Neurology (A.L.B., L.K.), SUNY, Stony Brook, NY; Department of Infectious Diseases (L.D.), Sahlgrenska University Hospital, Gothenburg, Sweden; Division of Infectious Diseases (G.P.W.), Department of Medicine, New York Medical College, Valhalla; Department of Neurology (G.G.), University of Kansas Medical Center; and Research Service, VAMHCS, and the Department of Neurology (C.T.B.), University of Maryland School of Medicine.


Abstract Objective: To provide evidence-based recommendations on the treatment of nervous system Lyme disease and post-Lyme syndrome. Three questions were addressed: 1) Which antimicrobial agents are effective? 2) Are different regimens preferred for different manifestations of nervous system Lyme disease? 3) What duration of therapy is needed? Methods: The authors analyzed published studies (1983-2003) using a structured review process to classify the evidence related to the questions posed. Results: The panel reviewed 353 abstracts which yielded 112 potentially relevant articles that were reviewed, from which 37 articles were identified that were included in the analysis. Conclusions: There are sufficient data to conclude that, in both adults and children, this nervous system infection responds well to penicillin, ceftriaxone, cefotaxime, and doxycycline (Level B recommendation). Although most studies have used parenteral regimens for neuroborreliosis, several European studies support use of oral doxycycline in adults with meningitis, cranial neuritis, and radiculitis (Level B), reserving parenteral regimens for patients with parenchymal CNS involvement, other severe neurologic symptomatology, or failure to respond to oral regimens. The number of children (≥8 years of age) enrolled in rigorous studies of oral vs parenteral regimens has been smaller, making conclusions less statistically compelling. However, all available data indicate results are comparable to those observed in adults. In contrast, there is no compelling evidence that prolonged treatment with antibiotics has any beneficial effect in post-Lyme syndrome (Level A).




This article has been cited by other articles:


Home page
NeurologyHome page
R. B. Stricker, L. Johnson, J. Halperin, C.T. Bever, A.L. Belman, L. Dotevall, G. Gronseth, L. Krupp, E. Logigian, E.D. Shapiro, et al.
PRACTICE PARAMETER: TREATMENT OF NERVOUS SYSTEM LYME DISEASE (AN EVIDENCE-BASED REVIEW): REPORT OF THE QUALITY STANDARDS SUBCOMMITTEE OF THE AMERICAN ACADEMY OF NEUROLOGY
Neurology, May 6, 2008; 70(19): 1719 - 1720.
[Full Text] [PDF]


Home page
NeurologyHome page
J. J. Halperin
Prolonged Lyme disease treatment: Enough is enough
Neurology, March 25, 2008; 70(13): 986 - 987.
[Full Text] [PDF]


Home page
J. Neuropsychiatry Clin. Neurosi.Home page
R. A. Hurley and K. H. Taber
Acute and Chronic Lyme Disease: Controversies for Neuropsychiatry
J Neuropsychiatry Clin Neurosci, February 1, 2008; 20(1): iv - 6.
[Full Text] [PDF]


Home page
JWatch NeurologyHome page
AAN Practice Parameter: Antimicrobial Therapy of Neuroborreliosis
Journal Watch Neurology, October 2, 2007; 2007(1002): 1 - 1.
[Full Text]

Correspondence:

Read all Correspondence

Practice Parameter: Treatment of nervous system Lyme disease (an evidence-based review)
Raphael B. Stricker, et al.
Neurology Online, 1 Nov 2007 [Full text]
Reply from the authors
John Halperin, MD, et al.
Neurology Online, 1 Nov 2007 [Full text]



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by AAN Enterprises, Inc.